31 Results for "

JH2

" in MedChemExpress (MCE) Product Catalog:
Products (31)

31 Results for "JH2" in MCE Product Catalog:

35
35 Publications Verification
Cat. No.: HY-117287
CAS No.: 1609392-27-9
Purity:  99.87%
Synonyms: BMS-986165
Deucravacitinib (BMS-986165) is an orally active allosteric inhibitor of tyrosine kinase 2 (TYK2), with an IC50 of 0.2 nM and a Ki of 0.02 nM against the JH2 domain of TYK2, and it exhibits selectivity over other JAK subtypes and most of the kinome. Deucravacitinib blocks IL-23, IL-12, p-STAT1/3 and Type I IFN signaling, and inhibits Th17/Th1-mediated psoriasis inflammation . Deucravacitinib can be used in research related to moderate-to-severe plaque psoriasis, inflammatory bowel disease and systemic lupus erythematosus [2].
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-102055
CAS No.: 2101955-00-2
Purity:  98.03%
JAK2 JH2 Tracer (Tracer 5) is a fluorescent probe for JAK2 JH2 domain, with a Kd value of 0.2 μM [2].
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-150096
CAS No.: 2272904-53-5
Purity:  98.98%
Synonyms: NDI-034858; TAK-279
Target:  

JAK

Research Areas:  

Inflammation/Immunology

Zasocitinib (NDI-034858) is a TYK2 inhibitor, target TYK2 JH2 domain with binding constant Kd of <200 pM .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-131968
CAS No.: 1771691-34-9
Purity:  99.92%
BMS-986202 is a potent, selective and orally active Tyk2 inhibitor that binds to Tyk2 JH2 with an IC50 value of 0.19 nM and a Ki of 0.02 nM. BMS-986202 is remarkably selective over other kinases including Jak family members. BMS-986202 is also a weak inhibitor of CYP2C19 with an IC50 value of 14 μM. BMS-986202 can be used for IL-23-driven acanthosis, anti-CD40-induced colitis, and spontaneous lupus research. BMS-986202 is a de novo deuterium .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-111745
CAS No.: 1797432-62-2
Purity:  99.35%
Target:  

JAK

Research Areas:  

Inflammation/Immunology

Tyk2-IN-5 (compound 6) is a potent, selective and orally active tyrosine kinase 2 (Tyk2) inhibitor that acts on the JH2 structural domain. Tyk2-IN-5 shows a Ki value of 0.086 nM for Tyk2 JH2 and an IC50 value of 25 nM for IFNα. Tyk2-IN-5 efficiently inhibits the production of IFNγ in a pharmacodynamic rat model and is fully efficacious in a rat model of arthritis .
loading...
    loading...
Cat. No.: HY-146186
CAS No.: 2923309-41-3
Purity:  95.47%
Target:  

JAK

Research Areas:  

Cancer

JAK2 JH2 binder-1 (compound 11) is a potent and selective JAK2 JH2 binder, with a Kd of 37.1 nM. JAK2 JH2 binder-1 has the potential for various myeloproliferative neoplasms research .
loading...
    loading...
Cat. No.: HY-153701S
CAS No.: 2417135-66-9
Synonyms: Envudeucitinib; ESK-001
Envudeucitinibum (Envudeucitinib) is a highly selective, allosteric and orally active TYK2 inhibitor binding to the JH2 domain of TYK2. Envudeucitinibum has no off-target effects on other kinases (JAK1-3). Envudeucitinibum reduces signaling and production of proinflammatory cytokines including IL-12, IL-23, IL-17, and type I interferons (IFNs). Envudeucitinibum can be used for the research of plaque psoriasis, systemic lupus erythematosus (SLE), and other immune-mediated diseases [2].
loading...
    loading...
Cat. No.: HY-169326S
CAS No.: 3057053-17-2
JAK2-IN-11 (Example 6) is a JAK2 kinase inhibitor with IC50 ≤10 nM against JH2 BIND WT/V617F. JAK2-IN-11 has antitumor activity .
loading...
    loading...
Cat. No.: HY-126242S
CAS No.: 1609391-90-3
Purity:  99.62%
Tyk2-IN-7 is an orally active TYK2 JH2 inhibitor, binds to TYK2 JH2 domain with IC50 and Ki.app of 0.00053 μM and 0.00007 μM, respectively. Tyk2-IN-7 provides a highly selective alternative to conventional TYK2 orthosteric inhibitors, inhibits TYK2/JAK1/JAK2 kinase domain. Tyk2-IN-7 can inhibit the IL-23 and IFN-α signaling pathways. Tyk2-IN-7 is commonly used in the study of inflammatory conditions such as colitis [2].
loading...
    loading...
Cat. No.: HY-101762
CAS No.: 2098466-94-3
Purity:  98.64%
Research Areas:  

Inflammation/Immunology

TyK2-IN-2 (Compoud 18) is a potent and selective TYK2 inhibitor with IC50s of 7 nM, 0.1 μM and 0.05 μM for TYK2 JH2, IL-23 and IFNα, respectively. TyK2-IN-2 also inhibits phosphodiesterase 4 (PDE4) with an IC50 of 62 nM. TyK2-IN-2 can be used for the research of inflammatory and autoimmune diseases .
loading...
    loading...
Cat. No.: HY-156409
CAS No.: 2368945-27-9
Purity:  99.94%
Target:  

JAK

Research Areas:  

Inflammation/Immunology

ABBV-712 is a selective and orally active inhibitor of Tyrosine kinase 2 (TYK2). ABBV-712 has EC50 values of 0.01, 0.19, and 0.17 μM for TYK2 JH2, TYK2 cells and human whole blood, respectively. ABBV-712 has anti-inflammatory activity and can be used in the research of autoimmune diseases .
loading...
    loading...
Cat. No.: HY-156466
CAS No.: 2848664-42-4
Purity:  99.95%
Research Areas:  

Inflammation/Immunology

QL-1200186 is a selective, orally active, allosteric inhibitor targeting the tyrosine kinase TYK2 pseudokinase domain JH2 (IC50=0.06 nM, TYK2 JH2), with 164-fold selectivity over TYK1 JH2 (IC50=9.85 nM,TYK1 JH2). QL-1200186 first stabilizes the TYK2 JH2 conformation, inhibits the activity of the JH1 catalytic domain, and blocks the IFNα, IL-12/IL-23-mediated JAK-STAT signaling pathway. QL-1200186 can inhibit the production of Th1/Th17 cell-related cytokines (such as IFNγ, IL-23), reduce immune cell activation, and has no significant effect on JAK1/2/3 kinase activity. QL-1200186 can significantly improve skin inflammation in the Imiquimod (HY-B0180)-induced psoriasis mouse model and reduce the Psoriasis Area and Severity Index (PASI) score. QL-1200186 can be used in the study of autoimmune diseases such as psoriasis and systemic lupus erythematosus (SLE) .
loading...
    loading...
Cat. No.: HY-E70873
Target:  

JAK

Research Areas:  

Cancer

TYK2 is a member of the JAK family of non-receptor tyrosine kinases that act together with signal transducer and activator of transcription (STAT) factors in mediating intracellular signal transduction. JAKs are characterized by dual kinase domain: a tyrosine kinase domain (JH1) that is preceded by a pseudokinase domain (JH2). Tyk2(JH1/JH2) Recombinant Human Active Protein Kinase is a recombinant Tyk2(JH1/JH2) protein that can be used to study Tyk2(JH1/JH2)-related functions .
loading...
    loading...
Cat. No.: HY-144031S
CAS No.: 2704587-24-4
Purity:  98.04%
Tyk2-IN-8 (compound 3) is a selective Tyk-2 inhibitor with an IC50 of 5.7 nM for TYK2-JH2. Tyk2-IN-8 inhibits JAK1-JH1 with IC50 of 3.0 nM. Tyk2-IN-8 can be used for the research of autoimmune disease .
loading...
    loading...
Cat. No.: HY-175983
CAS No.: 3026367-07-4
Target:  

JAK

Research Areas:  

Cancer

JAK1/TYK2-IN-5 (compound A1) is a JAK1/TYK2 inhibitor with Ki values of 0.0044 nM, 0.02 nM, 6.9 μM, 0.79 μM, 0.21 μM and 0.55 μM for TYK2 JH2, JAK1 JH2, JAK1 JH1, JAK2 JH1, JAK3 JH1 and TYK2 JH1, respectiverly. JAK1/TYK2-IN-5 inhibts IFNα induced TYK2/JAK1-mediated STAT activation .
loading...
    loading...
Cat. No.: HY-163304
CAS No.: 3010874-30-0
Target:  

JAK

Research Areas:  

Cancer

Tyk2-IN-16 is a selective and potent TYK2 inhibitor with an IC50 of <10 nM for TYK2-JH2. Tyk2-IN-16 inhibits pSTAT4 with an IC50 of <10 nM in NK92 cells (WO2023220046A1; compound 184) .
loading...
    loading...
Cat. No.: HY-E70874
Target:  

JAK

Research Areas:  

Cancer

TYK2 is a member of the JAK family of non-receptor tyrosine kinases that act together with signal transducer and activator of transcription (STAT) factors in mediating intracellular signal transduction. JAKs are characterized by dual kinase domain: a tyrosine kinase domain (JH1) that is preceded by a pseudokinase domain (JH2). TYK2(JH2) Recombinant Human Active Protein Kinase is a recombinant TYK2(JH2) protein that can be used to study TYK2(JH2)-related functions .
loading...
    loading...
Cat. No.: HY-149892S
CAS No.: 2376999-19-6
TYK2?JH2-IN-1-d3 is the a deuterated, orally active and selective TYK2 inhibitor (compound 4h), targeting to JH2 domain (IC50=0.1 nM) .
loading...
    loading...
Cat. No.: HY-163303
CAS No.: 3010873-44-3
Target:  

JAK

Research Areas:  

Inflammation/Immunology

Tyk2-in-15 (Compound 97) is a selective tyrosine kinase 2 (Tyk2) inhibitor with IC50 value ≤ 10 nM for Tyk2-JH2. Tyk2-IN-15 can be used in the study of inflammatory or autoimmune diseases .
loading...
    loading...
Cat. No.: HY-117287A
CAS No.: 1609392-28-0
Synonyms: BMS-986165 (hydrochloride)
Research Areas:  

Inflammation/Immunology

Deucravacitinib (BMS-986165) hydrochloride is an orally active allosteric inhibitor of tyrosine kinase 2 (TYK2), with an IC50 of 0.2 nM and a Ki of 0.02 nM against the JH2 domain of TYK2, and it exhibits selectivity over other JAK subtypes and most of the kinome. Deucravacitinib hydrochloride blocks IL-23, IL-12, p-STAT1/3 and Type I IFN signaling, and inhibits Th17/Th1-mediated psoriasis inflammation . Deucravacitinib hydrochloride can be used in research related to moderate-to-severe plaque psoriasis, inflammatory bowel disease and systemic lupus erythematosus [2].
loading...
    loading...